KPTI logo

KARYOPHARM THERAPEUTICS INC

KPTINASDAQ
πŸ† #5276 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track KPTI
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$907,258
Small Cap
πŸ“ˆRevenue Growth (YoY)
6.8%
Slowing
πŸ“ŠGross Margin
95.9%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for KPTI.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.01 – $10.99
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
22.7M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$146M
Last Q Revenue
$33M
P/E Ratio
β€”
P/S Ratio
0.0x
EPS (TTM)
$-12.84
Dividend Yield
β€”
Dilution (1yr)
+117.1%
KPTI logo

KARYOPHARM THERAPEUTICS INC

KPTI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$146Mβ–² +0.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
95.9%β–² +0.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$91Mβ–Ό βˆ’24.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$75Mβ–Ό βˆ’40.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
18.2Mβ–² +117.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$173Mβ–Ό βˆ’$41M YoY
StockOtter Β· stockotter.space

About KARYOPHARM THERAPEUTICS INC

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.